BRISBANE, Calif.--(BUSINESS WIRE)--Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR platform to create potential one-time curative therapies, today announced Janice Chen, Ph.D., chief technology officer and co-founder of Mammoth, will present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA, May 16 - 20, 2023.
The session, entitled Precise Genome Editing: One Goal, Multiple Avenues, will include presentations and discussions from prominent thought leaders in the field of gene editing that detail currently available platforms and strategies for enhancing precision and efficiency. Dr. Chen’s presentation will discuss the features of Mammoth’s ultracompact CRISPR systems and their translation for in vivo therapeutic applications. The session will also include a 25-minute panel discussion with Dr. Chen.
Title: Deploying ultracompact CRISPR systems for in vivo gene editing
Date and Time: May 16, 8:40 a.m - 9:00 a.m. PT
Location: Petree Hall D
More details about the workshop and panel are available on the ASGCT meeting website.
About Mammoth Biosciences
Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies, including Vertex Pharmaceuticals and Bayer AG to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.
